Normocapnia improves cerebral oxygen delivery during conventional oxygen therapy in carbon monoxide–exposed research subjects - 01/09/11
Abstract |
Study objective: We determine whether maintaining normocapnia during hyperoxic treatment of carbon monoxide–exposed research subjects improves cerebral oxygen delivery. Methods: This experiment used a randomized, single-blinded, crossover design. We exposed 14 human research subjects to carbon monoxide until their carboxyhemoglobin levels reached 10% to 12%. We then treated each research subject with 60 minutes of hyperoxia with or without normocapnia. Research subjects returned after at least 24 hours, were reexposed to carbon monoxide, and were given the alternate treatment. Relative changes in cerebral oxygen delivery were calculated as the product of blood oxygen content and middle cerebral artery velocity (an index of cerebral blood flow) as measured by transcranial Doppler ultrasonography. Results: Maintaining normocapnia during hyperoxic treatment resulted in significantly higher cerebral oxygen delivery compared with standard oxygen treatment (P <.05; 95% confidence interval at 60 minutes 2.8% to 16.7%) as a result of the prevention of hypocapnia-induced cerebral vasoconstriction and more rapid elimination of carbon monoxide due to increased minute ventilation. Conclusion: If severely poisoned patients respond like our research subjects, maintaining normocapnia during initial hyperoxic treatment of carbon monoxide poisoning may lead to increased oxygen delivery to the brain. Determining the effect of such a change in conventional treatment on outcome requires clinical studies. [Ann Emerg Med. 2002;40:611-618.]
El texto completo de este artículo está disponible en PDF.Esquema
| * | Supported in part by the Department of Anesthesia of The University Health Network, University of Toronto, and the Tobi and Ted Bekhor Foundation. |
| ** | A number of methods have been described for maintaining normocapnia without rebreathing and are thus suitable for application to carbon monoxide poisoning. The authors have developed one such method and applied for patent protection under the guidelines of the University of Toronto. After the completion of the studies described in the paper, the method was licensed to a commercial concern. |
| * | Address for reprints: Joseph A. Fisher, MD, FRCP(C), Department of Anesthesia, Toronto General Hospital, 200 Elizabeth Street, 3 Eaton N, Toronto, Ontario, Canada M5G 2C4; 416-340-4800 ext. 3071,fax 416-340-3698; E-mail joe.fisher@utoronto.ca |
Vol 40 - N° 6
P. 611-618 - décembre 2002 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?
